Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization

Hepatology Research

Volumn 39, Issue 7, 2009, Pages 724-738

  Fukushima, Juichi ^a   Kamada, Yoshihiro ^a   Matsumoto, Hitoshi ^a   Yoshida, Yuichi ^a   Ezaki, Hisao ^a   Takemura, Takayo ^a   Saji, Yukiko ^a   Igura, Takumi ^a   Tsutsui, Shusaku ^a   Kihara, Shinji ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a   Tamura, Shinji ^b   Kiso, Shinichi ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Minoh City Hospital   (Japan)

Author keywords

Adiponectin; Catalase; Kupffer cell phenotype polarization; Nonalcoholic steatohepatitis (NASH); Oxidative stress; PPAR

Indexed keywords

ADENOVIRUS VECTOR; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ARGINASE 1; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; INTERLEUKIN 10; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; KUPFFER CELL; LIVER CELL; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 67649598622     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00509.x     Document Type: Article

References (45)

1. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
2. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for adiponectin etiologic association. Hepatology 2002; 35: 367-72.
3. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
4. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-19.
5. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
6. Naveau S, Giraud V, Borotto E et al. Excess weight is a risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
7. Nair S, Mason A, Eason J et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-5.
8. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104: 531-43.
9. Friedman JM. Obesity in the new millennium. Nature 2000; 40: 632-4.
10. Shimomura I, Funahashi T, Takahashi M et al. Enhance expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
11. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
12. Friedmadin JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
13. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917-21.
14. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor A: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8.
15. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83: 461-5.
16. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
17. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
18. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84.
19. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75 in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
20. Yalniz M, Bahcecioglu IH, Ataseven H et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006; 2006: 34295: 1-5.
21. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
22. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNFα or adiponectin? Hepatology 2004; 40: 46-54.
23. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7.
24. Matsumoto H, Tamura S, Kamada Y et al. A deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 2006; 12: 3352-8.
25. Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-807.
26. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007; 47: 556-64.
27. Katz A, Nambi SS, Mather K et al. Quantitatibe insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
28. Moriya K, Todoroki T, Tsutsumi T et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem Biophys Res Commun 2001; 281: 1207-12.
29. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
30. Fruebis J, Tsao TS, Javorschi S et al. Proteolysic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-10.
31. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003; 112: 91-100.
32. Motoshima H, Wu X, Mahadev K et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-71.
33. Fujita K, Nishizawa H, Funahashi T et al. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437-42.
34. Harano Y, Yasui K, Toyama T et al. Fenofibrate, a peroxisome proliferator-activated receptor α agonist reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Intern 2006; 26: 613-20.
35. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
36. Raul G, Juan AC, Sandra N et al. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes. Free Radic Biol Med 2007; 43: 1439-52.
37. Kawanaka M, Mahmood S, Niiyama G et al. Control of oxidative stresss and reduction in biochemical markers by vitamin E treatment in patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2004; 29: 39-41.
38. Lavine JE Vitamin E treatment of nonalcoholic steatohepatitisin children: A pilot study. J Pediatr 2000; 36: 734-8.
39. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-32.
40. Kumada M, Kihara S, Ouchi N et al. Adiponectin specifically increased tissue inhibitor of metalloprotease-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-9.
41. Maeda N, Takahashi M, Funahashi T et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
42. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-63.
43. Hiuge A, Tenenbaum A, Maeda N et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007; 27: 635-41.
44. Tsuchida A, Yamauchi T, Takekawa S et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-70.
45. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21: 89-104.